Adicet Bio (FRA:1IJ) ROE % Adjusted to Book Value: -136.20% (As of Mar. 2026)


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €7.20
! 2 Warning Signs
View Full Analysis

What is Adicet Bio ROE % Adjusted to Book Value?

Adicet Bio FRA:1IJ -5.26% 31 ROE % Adjusted to Book Value is -136.20% as of Mar. 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Adicet Bio's ROE % for the quarter that ended in Mar. 2026 was -54.48%. Adicet Bio's PB Ratio for the quarter that ended in Mar. 2026 was 0.40. Adicet Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -136.20%.

Adicet Bio ROE % Adjusted to Book Value Related Terms

Adicet Bio ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Adicet Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio ROE % Adjusted to Book Value Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -14.86 -19.68 -144.19 -176.11 -144.32

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -163.44 -215.03 -148.71 -206.95 -136.20

FRA:1IJ vs EDSA, GOSS, HRTX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Adicet Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Adicet Bio's ROE % Adjusted to Book Value falls into.


FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio ROE % Adjusted to Book Value Calculation

Adicet Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-63.50% / 0.44
=-144.32%

Adicet Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-54.48% / 0.40
=-136.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -136.20% mean?
Adicet Bio (FRA:1IJ) has a ROE % Adjusted to Book Value of -136.20% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Adicet Bio and its competitors.
Is Adicet Bio's ROE % Adjusted to Book Value too high?
Adicet Bio's current ROE % Adjusted to Book Value is -136.20%. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's ROE % Adjusted to Book Value compare to EDSA and GOSS?
Adicet Bio's ROE % Adjusted to Book Value of -136.20% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Adicet Bio and its competitors. Adicet Bio's current ROE % Adjusted to Book Value is -136.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current ROE % Adjusted to Book Value of -136.20%. The current ROE % Adjusted to Book Value is -136.20%. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current ROE % Adjusted to Book Value is -136.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.20
Price